Bone marrow transplants from unrelated donors for leuToxicity kaemias are increasing greatly in number and also in proportion to matched sibling donor transplants. The panel has
Increasing age and degree of mismatch each increase the considered unrelated donor transplant (UD-BMT) on the basis probability of transplant-related mortality and morbidity and of efficacy, toxicity and indications in leukaemias. The conneed to be taken into account when assessing the use of UDclusions and statements are based largely but not exclusively BMT in any situation. In young (less than 20 years) good risk on information provided at the Consensus Conference.
patients, the mortality of the procedure is of the order of 15%, which rises in older patients (at 45 years to 30% or more).
Transplants with an HLA mismatched (A, B or DR) marrow Efficacy have a high toxicity compared with matched marrow and cannot be equated with sibling transplants. Unrelated bone marrow transplants for some types of leuThere are, to date, few published studies concerning quality kaemia can produce prolonged quiescence and, in some of life in recipients of UD-BMT. In order to inform decision cases, eradication of disease.
making, such information must be collected using well valiData based on serologically matched donors at HLA A, B dated standardised tests. and DR suggest that matched unrelated transplants may have similar survival to sibling transplants in comparable disease states. This is accepted as a reasonable statement but begs the question of what is implied by 'matched' in unrelated transplants. Much of the data concerning the survival and toxicity Indications in unrelated transplants has come from studies using serological typing. The effect of molecular typing on outcome may alter indications.
Information which allows the classification of various diseases into good, standard and high risk is essential in allowing comInformation on the place of sibling transplants compared with chemotherapy and autologous transplants in the manageparative assessment of treatments including UD-BMT. Evidence suggests that the results of UD-BMT are better ment of some leukaemias has been provided by randomised studies organised by the EORTC and the MRC. These define when performed early in some diseases. The timing of UD-BMT, however, depends on the consideration of other treatthe place of sibling bone marrow transplantation in the management of acute leukaemias. Conclusions drawn from these ment options. For patients with CML in chronic phase or accelerated studies on the presence or absence of benefit of sibling transplants may apply to unrelated transplants.
phase, UD-BMT should be considered as the best available treatment at present for patients without a matched sibling In a few situations, the evidence for efficacy is based on the level 1 documentation of zero survival following conventional donor providing that the unrelated donor provides a 'close match' (level 1c evidence). therapy but with some survivors following transplant (eg childhood ALL with early bone marrow relapse). However, in situFor patients with AML in first remission, UD-BMT has little place at the present time. In second CR, it may be considered, ations where alternative therapies occasionally succeed, level 1 evidence from randomised trials is rarely available to help though its role in relation to other therapies requires further evaluation. UD-BMT has a clear place in a subgroup of in decision making.
There is variation in outcome reported from different patients with initial refractory disease, secondary AML and high risk myelodysplastic syndromes (level 1c evidence). sources for particular conditions. In part, this may be because subdivisions of different types of leukaemia are not always For a small group of children with very high risk ALL in first remission, and for children in second remission who have accurately defined. Attempts to identify subgroups and to compare 'like with like' are essential even though they make sustained an early bone marrow relapse, data suggest that survival may be improved by UD-BMT (level 1c evidence). Simidata collection and comparisons more arduous.
It is important that rigorous economic evaluations and lar criteria may apply to adult ALL but present data are even more limited. quality of life studies are carried out alongside 'like with like' comparisons.
The results of UD-BMT for desperate disease (such as CML in blast crisis or acute leukaemia in overt relapse) are discouraging (10% or less survival) and are associated with marked and often unquantitated toxicity. It may be considered that toxicity inflicted on the unsuccessful recipients negates the ful in terms of survival.
Information for decision-making
Policies on anonymity differ widely throughout the world. There are good reasons to maintain strict anonymity between donor and recipient despite theoretical problems in donor UD-BMT should only be carried out where there are facilities recruitment. The potential problems of breaking this anonyfor full characterisation of the recipient's disease, molecular mity seem to outweigh the benefits of disclosure. Systematic HLA typing available and guaranteed reporting to national or investigation of these matters should be carried out. international registries.
Further research addressing the complex ethical and psyFor conditions where there is no level 1 evidence and there chosocial issues surrounding related and unrelated donors, is doubt about the benefits of UD-BMT vs other therapies, the should be undertaken. procedure is only justified as part of a randomised trial (or formal pilot for such a trial).
With respect to more general planning of services it is Scientific organising committee important to research the issue of whether UD-BMT should take place in a limited number of specialised units.
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